Showing results (691-700 of 713) with videos related to
Sort By:
Pageof 72
The Journal of General Virology|October 27, 2021
ICTV Virus Taxonomy Profile: Herpesviridae 2021Derek Gatherer, Daniel P Depledge, Carol A Hartley, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2021
Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic LeukemiaClaire Roddie, Juliana Dias, Maeve A O'Reilly, et al.JMIR Research Protocols|October 4, 2019
VEROnA Protocol: A Pilot, Open-Label, Single-Arm, Phase 0, Window-of-Opportunity Study of Vandetanib-Eluting Radiopaque Embolic Beads (BTG-002814) in Patients With Resectable Liver MalignanciesLaura Beaton, Henry F J Tregidgo, Sami A Znati, et al.Science (New York, N.Y.)|March 31, 2022
From telomere to telomere: The transcriptional and epigenetic state of human repeat elementsSavannah J Hoyt, Jessica M Storer, Gabrielle A Hartley, et al.Journal of Vascular and Interventional Radiology : JVIR|May 8, 2022
Phase 0 Study of Vandetanib-Eluting Radiopaque Embolics as a Preoperative Embolization Treatment in Patients with Resectable Liver MalignanciesLaura Beaton, Henry F J Tregidgo, Sami A Znati, et al.Haematologica|May 28, 2026
A phase I/II study of twice-weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myelomaOmar Nadeem, Robert A Redd, Peter M Barth, et al.BJA Open|July 1, 2024
Cardiopulmonary exercise variables and their association with postoperative morbidity and mortality after major oesophagogastric cancer surgery-a multicentre observational studyMalcolm A West, Saqib Rahman, Sandy Jack, et al.Molecular Cancer Therapeutics|August 2, 2018
Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate CancerSong Cho, Francesca Zammarchi, David G Williams, et al.Cell Death & Disease|March 29, 2022
Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in transJ M Vicencio, R Evans, R Green, et al.Lancet (London, England)|June 14, 2026
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trialMeletios A Dimopoulos, Fredrik Schjesvold, Chengcheng Fu, et al.Pageof 72